GSK secures European nod for clearer-to-utilize Shingrix prefilled syringe
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
Global biopharma powerhoutilize GSK has announced that the European Commission has approved a new prefilled syringe version of its shingles vaccine, Shingrix.
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration. The new prefilled syringe eliminates this step, streamlining the vaccination process.
“This new presentation of Shingrix has been designed to improve ease of administration, assisting healthcare professionals to provide protection against shingles,” declared Tony Wood, Chief Scientific Officer, GSK.
“Shingles is a painful disease that can have serious and long-lasting complications. It affects millions of people each year in Europe, often imposing a greater burden on people living with common chronic diseases such as cardiovascular disease and diabetes. GSK is proud to support the healthcare community by building administration of its shingles vaccine clearer.”
The approval follows data confirming that the prefilled syringe is technically comparable to the existing two-vial presentation. Importantly, the alter does not alter the vaccine’s indication or dosing.
Leave a Reply